Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10

Journal of Immunology

Volumn 191, Issue 6, 2013, Pages 3186-3191

  Doyle Cooper, Colleen ^a   Hudson, Krystalyn E ^a   Cooper, Anthony B ^a   Ota, Takayuki ^a   Skog, Patrick ^a   Dawson, Phillip E ^a   Zwick, Michael B ^a   Schief, William R ^a   Burton, Dennis R ^a,b   Nemazee, David ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BROADLY NEUTRALIZING ANTIBODY HIV ANTIBODY 4E10; CARDIOLIPIN ANTIBODY; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NEUTRALIZING ANTIBODY; RAG1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TRANSGENE;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE KNOCK-IN TECHNIQUES; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; IMMUNE TOLERANCE; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 84884215837     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301285     Document Type: Article

References (38)

1. Baba, T. W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehunie, L. A. Cavacini, M. R. Posner, H. Katinger, G. Stiegler, et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6: 200-206.
2. Conley, A. J., J. A. Kessler, II, L. J. Boots, P. M. McKenna, W. A. Schleif, E. A. Emini, G. E. Mark, III, H. Katinger, E. K. Cobb, S. M. Lunceford, et al. 1996. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J. Virol. 70: 6751-6758.
3. Gauduin, M. C., P. W. Parren, R. Weir, C. F. Barbas, D. R. Burton, and R. A. Koup. 1997. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3: 1389-1393.
4. Mascola, J. R., G. Stiegler, T. C. VanCott, H. Katinger, C. B. Carpenter, C. E. Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L. Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6: 207-210.
5. Mascola, J. R., M. G. Lewis, G. Stiegler, D. Harris, T. C. VanCott, D. Hayes, M. K. Louder, C. R. Brown, C. V. Sapan, S. S. Frankel, et al. 1999. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73: 4009-4018.
6. Parren, P. W., H. J. Ditzel, R. J. Gulizia, J. M. Binley, C. F. Barbas, III, D. R. Burton, and D. E. Mosier. 1995. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 9: F1-F6.
7. Parren, P. W., P. A. Marx, A. J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J. P. Moore, and D. R. Burton. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75: 8340-8347.
8. Hessell, A. J., P. Poignard, M. Hunter, L. Hangartner, D. M. Tehrani, W. K. Bleeker, P. W. Parren, P. A. Marx, and D. R. Burton. 2009. Effective, lowtiter antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15: 951-954.
9. Hessell, A. J., L. Hangartner, M. Hunter, C. E. Havenith, F. J. Beurskens, J. M. Bakker, C. M. Lanigan, G. Landucci, D. N. Forthal, P. W. Parren, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104.
10. Hessell, A. J., E. G. Rakasz, P. Poignard, L. Hangartner, G. Landucci, D. N. Forthal, W. C. Koff, D. I. Watkins, and D. R. Burton. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5: e1000433.
11. Ota, T., C. Doyle-Cooper, A. B. Cooper, K. J. Doores, M. Aoki-Oto, K. Le, W. R. Schief, R. T. Wyatt, D. R. Burton, and D. Nemazee. 2013. B cells from knock-in mouse expressing broadly neutralizing HIV antibody b12 carry an innocuous BCR responsive to HIV vaccine candidates. J. Immunol. 191: 3179-3185.
12. Burton, D. R., R. L. Stanfield, and I. A. Wilson. 2005. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. USA 102: 14943-14948.
13. Buchacher, A., R. Predl, K. Strutzenberger, W. Steinfellner, A. Trkola, M. Purtscher, G. Gruber, C. Tauer, F. Steindl, A. Jungbauer, et al. 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10: 359-369.
14. Kunert, R., S. Wolbank, G. Stiegler, R. Weik, and H. Katinger. 2004. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res. Hum. Retroviruses 20: 755-762.
15. Zwick, M. B., A. F. Labrijn, M. Wang, C. Spenlehauer, E. O. Saphire, J. M. Binley, J. P. Moore, G. Stiegler, H. Katinger, D. R. Burton, and P. W. Parren. 2001. Broadly neutralizing antibodies targeted to the membraneproximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75: 10892-10905.
16. Cardoso, R. M., M. B. Zwick, R. L. Stanfield, R. Kunert, J. M. Binley, H. Katinger, D. R. Burton, and I. A.Wilson. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusionassociated motif in gp41. Immunity 22: 163-173.
17. Ofek, G., M. Tang, A. Sambor, H. Katinger, J. R. Mascola, R. Wyatt, and P. D. Kwong. 2004. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78: 10724-10737.
18. Alam, S. M., M. Morelli, S. M. Dennison, H. X. Liao, R. Zhang, S. M. Xia, S. Rits-Volloch, L. Sun, S. C. Harrison, B. F. Haynes, and B. Chen. 2009. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA 106: 20234-20239.
19. Scherer, E. M., D. P. Leaman, M. B. Zwick, A. J. McMichael, and D. R. Burton. 2010. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc. Natl. Acad. Sci. USA 107: 1529-1534.
20. Haynes, B. F., J. Fleming, E. W. St Clair, H. Katinger, G. Stiegler, R. Kunert, J. Robinson, R. M. Scearce, K. Plonk, H. F. Staats, et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308: 1906-1908.
21. Yang, G., T. M. Holl, Y. Liu, Y. Li, X. Lu, N. I. Nicely, T. B. Kepler, S.M. Alam, H. X. Liao, D. W. Cain, et al. 2013. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J. Exp. Med. 210: 241-256.
22. Verkoczy, L., Y. Chen, H. Bouton-Verville, J. Zhang, M. Diaz, J. Hutchinson, Y. B. Ouyang, S. M. Alam, T. M. Holl, K. K. Hwang, et al. 2011. Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls. J. Immunol. 187: 3785-3797.
23. Scherer, E. M., M. B. Zwick, L. Teyton, and D. R. Burton. 2007. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 21: 2131-2139.
24. Vcelar, B., G. Stiegler, H. M. Wolf, W. Muntean, B. Leschnik, S. Mehandru, M. Markowitz, C. Armbruster, R. Kunert, M. M. Eibl, and H. Katinger. 2007. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 21: 2161-2170.
25. Casellas, R., T. A. Shih, M. Kleinewietfeld, J. Rakonjac, D. Nemazee, K. Rajewsky, and M. C. Nussenzweig. 2001. Contribution of receptor editing to the antibody repertoire. Science 291: 1541-1544.
26. Correia, B. E., Y. E. Ban, M. A. Holmes, H. Xu, K. Ellingson, Z. Kraft, C. Carrico, E. Boni, D. N. Sather, C. Zenobia, et al. 2010. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18: 1116-1126.
27. Avery, D. T., S. L. Kalled, J. I. Ellyard, C. Ambrose, S. A. Bixler, M. Thien, R. Brink, F. Mackay, P. D. Hodgkin, and S. G. Tangye. 2003. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. 112: 286-297.
28. Hardy, R. R., C. E. Carmack, S. A. Shinton, J. D. Kemp, and K. Hayakawa. 1991. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J. Exp. Med. 173: 1213-1225.
29. Duong, B. H., T. Ota, M. Aoki-Ota, A. B. Cooper, D. Ait-Azzouzene, J. L. Vela, A. L. Gavin, and D. Nemazee. 2011. Negative selection by IgM superantigen defines a B cell central tolerance compartment and reveals mutations allowing escape. J. Immunol. 187: 5596-5605.
30. Ota, T., C. Doyle-Cooper, A. B. Cooper, M. Huber, E. Falkowska, K. J. Doores, L. Hangartner, K. Le, D. Sok, J. Jardine, et al. 2012. Anti-HIV B Cell lines as candidate vaccine biosensors. J. Immunol. 189: 4816-4824.
31. Taki, S., F. Schwenk, and K. Rajewsky. 1995. Rearrangement of upstream DH and VH genes to a rearranged immunoglobulin variable region gene inserted into the DQ52-JH region of the immunoglobulin heavy chain locus. Eur. J. Immunol. 25: 1888-1896.
32. Chen, C., Z. Nagy, E. L. Prak, and M. Weigert. 1995. Immunoglobulin heavy chain gene replacement: a mechanism of receptor editing. Immunity 3: 747-755.
33. Chen, Y., J. Zhang, K. K. Hwang, H. Bouton-Verville, S. M. Xia, A. Newman, Y. B. Ouyang, B. F. Haynes, and L. Verkoczy. 2013. Common Tolerance Mechanisms, but Distinct Cross-Reactivities Associated with gp41 and Lipids, Limit Production of HIV-1 Broad Neutralizing Antibodies 2F5 and 4E10. J. Immunol. 191:1260-1275.
34. Huang, J., G. Ofek, L. Laub, M. K. Louder, N. A. Doria-Rose, N. S. Longo, H. Imamichi, R. T. Bailer, B. Chakrabarti, S. K. Sharma, et al. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406-412.
35. Aït-Azzouzene, D., D. H. Kono, R. Gonzalez-Quintial, L. J. McHeyzer-Williams, M. Lim, D. Wickramarachchi, T. Gerdes, A. L. Gavin, P. Skog, M. G. McHeyzer-Williams, et al. 2010. Deletion of IgG-switched autoreactive B cells and defects in Fas(lpr) lupus mice. J. Immunol. 185: 1015-1027.
36. Chan, T. D., K. Wood, J. R. Hermes, D. Butt, C. J. Jolly, A. Basten, and R. Brink. 2012. Elimination of germinal-center-derived self-reactive B cells is governed by the location and concentration of self-antigen. Immunity 37: 893-904.
37. Lang, J., M. Jackson, L. Teyton, A. Brunmark, K. Kane, and D. Nemazee. 1996. B cells are exquisitely sensitive to central tolerance and receptor editing induced by ultralow affinity, membrane-bound antigen. J. Exp. Med. 184: 1685-1697.
38. Russell, D. M., Z. Dembić, G. Morahan, J. F. Miller, K. Bü rki, and D. Nemazee. 1991. Peripheral deletion of self-reactive B cells. Nature 354: 308-311.